Mitsubishi gains Asia rights to Regeneron's pain candidate

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) granted Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) exclusive development and commercialization rights to fasinumab ( REGN475) in 11 Asian countries, including Japan, South Korea and Taiwan. The deal does not include China.

Regeneron began a Phase IIb/III trial of the mAb against nerve growth factor (NGF) in mid-2015 to treat pain associated with osteoarthritis (OA) of the knee or hip. ...